Lapatinib, a selective inhibitor of the HER2 target, has shown inhibitory effects on HER2-positive GBM cells in some early in vitro and animal studies, but this does not necessarily translate into significant clinical treatment effects. The gene discussed is ERBB2; the disease is glioblastoma.